Prophylaxis and therapy of viral infections in pediatric patients treated for malignancy

Abstract

Infections are still an important cause of mortality and morbidity in pediatric cancer patients. Most of the febrile episodes in immunocompromised patients are classified as a fever of unknown origin (FUO) while bacteria are the more frequent causes of documented infections. Viral infections are also feared during chemotherapy but less data are available on their incidence and morbidity. We reviewed the literature on incidence, morbidity, and mortality of viral infections in children undergoing chemotherapy and discussed the evidence concerning the prophylaxis and the therapy.

Introduction

During the last decades, survival rates in pediatric cancer have continuously increased. Infections are an important cause of morbidity and mortality for children with malignancy. Infectious complications not only contribute to mortality but also prolong hospitalisation, delay chemotherapy delivery, affect quality of life and increase healthcare utilization and costs.

The most frequent causal pathogens of febrile neutropenia (FN) are bacteria or fungi; they are identified and confirmed by culture in only 25–30% of the cases. In other 15–25% of patients with FN, bacterial or fungal infections are suspected on clinical findings. The remaining 50% of cases are classified as fever of unknown origin (FUO) and may be caused by other pathogens, namely virus, that are more difficult to detect by conventional methods.¹

Generally viral infections are suspected on the basis of clinical data, laboratory findings and lack of other identified sources of fever; nevertheless, often it is difficult to confirm a suspected viral etiology on the basis of clinical findings with the isolation of the virus.²

Understanding the prevalence and the characteristics of viral infections can improve the treatment of febrile episodes in cancer patients. Unfortunately, very few studies on viral diseases in pediatric cancer patients have been published.

The respiratory viruses are one of the more frequent cause of viral infection in cancer patients and are implicated in the commonest seasonal-related community-acquired infections. Christensen observed in a prospective follow-up study all the febrile episodes during 12 months in a pediatric oncology department; nineteen viral infections were diagnosed in 250 febrile episodes. By molecular diagnosis, he increased the microbiologic verification of infections to 35%. Overall, viral infections were rare but he reported a fatal complication caused by respiratory syncytial virus (RSV). Moreover he found a lower number of febrile episodes in solid tumor patients while the viral infections were more frequent in this group than in patients with hematologic malignancies.³

Katsimpardi et al collected retrospectively all infectious episodes in children with acute lymphoblastic leukemia (ALL) from a single institution, i.e. 610 episodes over 6 years. The objective was to assess the type, frequency, severity and outcome of all infectious episodes. Viral infections were diagnosed in about 10% of episodes. The most frequent diagnosis were varicella-zoster (VZV) and herpes simplex virus (HSV) infections. Most of the severe infections occurred during the induction therapy (bacteremia and FUO), while viral infections were more common during maintenance treatment.⁴

In another study, viral pathogens were identified in 34% of the episodes of FN.⁵ This study compared patients with FUO with patients affected by viral infections; patients with FUO had shorter duration of fever and hospitalisation; only few cases developed clinical complication. This study described less FUO (53% of total FN) and more diagnoses of viral infections compared with other similar observational studies.⁶ The majority of bacteremia findings diagnosed by blood culture were detected within 24 hours and most FUO (66%) had fever for less than 24 hours. The authors emphasize that increasing detection of viral infections can improve treatment of FN, establishing different, risk based approaches for management of fever in pediatric cancer patients.

Despite the paucity of studies on epidemiological aspects of viral diseases in children undergoing chemotherapy, literature reports many case descriptions of severe or lethal viral infections. These reports are in opposition with the common opinion that viruses are quite harmless in cancer patients.^7–11 We reviewed literature on incidence, morbidity and mortality of viral infections in children undergoing chemotherapy and discussed the evidence concerning the prophylaxis and the therapy.

Methods

For the literature search we used the key words prophylaxis, viral infections, pediatric malignancy and therapy, viral infections, pediatric malignancy. The literature search was limited to English language papers and the period analyzed was from 1 January 1990 to 31 July 2010. Reference list of papers selected by literature search was also used as source, if necessary. The results of the search were first discussed and scored by the authors and then presented for the final discussion and approval to a expert meeting held in Florence on 12 and 13 October 2010 where the representatives of centers belonging to Italian Association of Pediatric Hematology Oncology (AIEOP) attended. The scoring system proposed by Infectious Diseases Society of America was adopted to define the quality of evidence and strength of recommendations (Table 1).

Table 1. Quality of evidence and Strength of recommendations according to the CDC grading system.²³.

Quality of evidence

Strength of recommendation

I Evidence from at least one well-executed randomized trial II Evidence from at least one well-designed clinical trial without randomization; cohort or case-controlled analytic studies (preferably from more than one center; multiple time-series studies or dramatic results from uncontrolled experiments) III Evidence from opinion of respected authorities based on clinical experience, descriptive studies, or reports or interactions) from expert committees

A Strong evidence for efficacy and substantial clinical benefit Strongly recommended B Strong or moderate evidence for efficacy, but only limited clinical benefit Generally recommended C Insufficient evidence for efficacy, or efficacy does not outweigh possible adverse consequences (e.g. drug toxicity or cost of chemoprophylaxis or alternative approaches Optional D Moderate evidence against efficacy or for adverse outcome Generally not recommended E Strong evidence against efficacy or for adverse outcome Never recommended

Varicella-Zoster virus

Like other herpesvirus infection, varicella-zoster virus (VZV) can remain latent after primary infection; immunosuppression caused by chemotherapy increases the likelihood of reactivation. Before the introduction of acyclovir and hyper-immune immunoglobulin, mortality caused by disseminated varicella was high. Moreover, in ALL patients who had developed previously VZV, Herpes zoster may occur up to 25%. Prophylaxis with VZV immunisation has decreased this complication.

Leukemic patients and parents should be informed about VZV transmission and advised of strategies on how to avoid exposure (AIII). Family members, household contacts and healthcare workers known to be VZV-seronegative or children with no history of VZV infection should be given varicella vaccine (BIII). All patients with varicella or disseminated zoster should be placed under airborne and contact isolation. The isolation should continue as long as the rash remains vesicular and until all lesions are crusted (BIII).

Passive immunization with human Varicella-zoster immunoglobulin (VZIG) should be given as soon as possible after exposure (<96 h) to VZV-seronegative leukemic patients on chemotherapy (AII). Where passive immunization is not available, post-exposure prophylaxis with acyclovir starting 7–9 days after exposure is recommended (20 mg/kg four times daily for 7 days – max 800 mg/dose) (AIII). If a second exposure occurs more than 21 days after a dose of passive immunization or after the administration of the antiviral prophylaxis, a prophylaxis should be readministered (CIII).

In case of disease, antiviral treatment reduces the duration of viral replication and clinical manifestation. Patients treated for leukemia who have a varicella-like rash should be started immediately on i.v. acyclovir 20 mg/kg every 8 h for 5–10 days (AI). Therapy (i.v./oral) should be given for at least 7 days and to be continued until 2 days after all lesions are crusted (AI). Vigilance for the possibility of visceral VZV disease without mucocutaneous manifestations (for example, in cases of encephalitis, pneumonitis or hepatitis) is needed, and i.v. acyclovir should be considered in such cases (AIII). Foscarnet (60 mg/kg every 12 h i.v.) or cidofovir (5 mg/kg once a week for 2 weeks, then (if still needed) once every 2 weeks combined with pro-benecide and i.v. hydration) are alternatives for anti-VZV treatment in a case of acyclovir-resistant VZV infection (AIII).^12–14

Herpes simplex virus

HSV (herpes simplex virus) (type 1 > type 2) commonly cause mucocutaneous lesions in patiens with hematologic malignancies. HSV reactivation is frequent both in patients with acute leukemia during induction chemotherapy and in SCT recipients. The incidence of HSV lesions among seropositive patients during chemotherapy is high in many observational studies in adults. In a prospective cohort study in pediatric oncology patients, HSV was detected from mouth swab and blood specimen during FN; prevalence of HSV infection was low, oral HSV was associated with longer median duration of mucositis but was not associated with prolonged fever or neutropenia. It is unknown whether early intervention with acyclovir can reduce the duration of mucositis.¹⁵

Primary HSV infection in patients treated for leukemia is unusual, and antiviral drug prophylaxis is thus not recommended in HSV-seronegative leukemic patients during chemotherapy (DIII).

ALL patients during the phase of induction that are HSV-seropositive may be considered for antiviral drug prophylaxis with acyclovir (level of recommendation CIII). The therapy of choice for severe mucocutaneous or visceral HSV disease is intravenous acyclovir 250 mg/m² or 5 mg/kg every 8 h for 7–10 days (AI). Oral acyclovir for 10 days (AI) is considered as alternative for less serious manifestations of HSV disease; for adult patients only valaciclovir p.o. for 10 days (BIII) or famciclovir p.o. for 10 days (BIII) may be considered as well. For HSV pneumonia or HSV meningitis and encephalitis, a higher dose of i.v. acyclovir 500 mg/m² or 10 mg/kg every 8 h for 14–21 days should be considered (CIII).¹³

Cytomegalovirus

Cytomegalovirus (CMV) is a significant cause of morbidity and mortality in patients who had undergone hematopoietic stem cell transplantation (HSCT) but it has increasingly reported also in leukemic patients treated with fludarabine or monoclonal antibodies (alemtuzumab). We adopted the ECIL recommendations (European Conference on Infections in Leukemia) for CMV prophylaxis in patients non-SCT (Table 2).

Table 2. Cytomegalovirus prophylaxis.

Immune globulin for prevention of CMV infection or disease is not recommended	EII
Leukemia patients with a lesser degree of immunosuppression do not need a specified prophylactic strategy but CMV disease must be in the differential diagnosis if symptoms compatible with CMV develop
Routine monitoring and pre-emptive therapy are not considered necessary in other hematology patients	DIII
Routine antiviral prophylaxis is not recommended	DIII

Cytomegalovirus therapy

Patients with symptoms compatible with CMV but without manifest organ involvement should be carefully assessed. In patients with suspected CMV organ involvement, the risks and benefits of antiviral therapy should be considered before a decision is made. The choice of an antiviral agent will depend on the individual patient, the risk for progression to CMV disease and the risk for side effects of the chosen drug. Limited data are available about intravenous immunoglobulin i.v. (IVIG). and it seems not add benefit in addition to antiviral therapy; the evidence for their use is CII.^16–18 For therapy see Table 3.

Table 3. Cytomegalovirus therapy.

Treatment of CMV pneumonia
Antiviral therapy with ganciclovir is recommended	AII
Foscarnet can be used in place of ganciclovir	AIII
Cidofovir or the combination of foscarnet and ganciclovir can be used as second-line therapy	BII

Other types of CMV disease
Either i.v. ganciclovir or foscarnet administration without the addition of immune globulin is recommended	BII
Cidofovir or the combination of i.v. ganciclovir and foscarnet can be used as second-line therapy for CMV disease	BII

Epstein-barr virus

We adopted the ECIL recommendation for Epstein-barr virus (EBV). Routine monitoring and pre-emptive therapy are not considered necessary out of HSCT setting (CIII).¹³

Influenza

Influenza causes significant morbidity and mortality in immunocompromised children. Prevention is based on vaccination. There is only one published study in which oral Oseltamivir prophylaxis 75 mg once daily for 8 weeks during an influenza season has been used in the prevention of influenza infection in immunocompromised children with few side-effects. It is a prospective, non-blinded, non-controlled observational study (CIII).¹⁹

There are no large clinical trials about influenza treatment. Oseltamivir can prevent progression to pneumonia and can be used in children starting from 1 year of age, Zanamivir in children aged >7 years of age. It is still unknown the risk to develop resistance to antiviral agents.²⁰

Respiratory syncytial virus

Respiratory syncytial virus (RSV) is a common cause of infection in immunocompetent and immunocompromised host. The majority of patients affected by RSV and by other respiratory virus experience mild symptoms, but occasionally they can cause pneumonia and marrow suppression with consequent delay of chemotherapy administration.³

In a review on a population of children with acute myeloid leukemia (AML) prevalence of RSV infection was low, but related mortality among children with RSV infection was high. Palivizumab is a humanized monoclonal immunoglobulin used for prophylaxis in children younger than 2 years of age with chronic lung disease who require medical therapy and those born at 32 weeks gestation or earlier; its use has been suggested in some congenital heart disease. The authors don't believe that prophylactic Palivizumab is routinely indicated in children with AML because of the low risk to catch RSV infection; moreover the rarity of this infection preclude the possibility of a randomised trial (level of evidence DIII).⁹

About treatment, a Cochrane review on children hospitalised for RSV infection underline that it is not demonstrated a significant benefit of IVIG treatment added to supportive care compared with supportive care alone.²¹ The role of Ribavirin, an antiviral agent licensed for severe RSV infection, is unclear too (level of evidence, CIII).

Parvovirus

Cytopenia caused by chemotherapy is indistinguishable from that associated with infection or other causes. A prospective study detected Parvovirus B19 DNA in pediatric patients with unexpected cytopenia during chemotherapy for ALL; classical symptoms like erythema infectiosum were absent. In some situations, for example during manteinance, cytopenia can cause suspension or reduce intensity of treatment. The authors suggest screening for parvovirus B19 in pediatric patients with ALL and unexplained cytopenia. Treatment with IVIG has proven to be successful although some studies could not document a clear benefit (level of evidence CIII).²²

Enterovirus

In immunocompromised children, enterovirus can cause life-theatening infections such as myocarditis, meningitis and encephalitis. Early diagnosis and treatment with IVIG together with supportive care may improve the outcome. In a retrospective study, children who received high dose of IVIG (2 gr/kg) developed early negative viral load versus children treated with low dose of IVIG (400 mg/kg) (level of evidence CIII).¹⁰